AGENDA | JULY 20 | 12:00 PM EDT
12:00 - 12:05 PM
Welcome & Opening Remarks
Presented By:
Joseph Sullivan, CEO & Founder - Emmetropes
12:05 - 12:35 PM
Fireside Chat
Participant:
Jean-Frédéric Chibret, President - Théa
Interviewed By:
Joseph Sullivan, CEO & Founder - Emmetropes
12:35 - 12:50 PM
Europe as an Innovation Powerhouse in Ophthalmology
Presented By:
Luis Diaz-Santana, Head of Ophthalmology - Cambridge Consultants
12:50 - 2:05 PM
Company Showcase
Moderated By:
Joseph Sullivan, CEO & Founder - Emmetropes
Visotec GmbH | Helge Sudkamp - CEO
GenSight Biologics | Magali Taiel, MD - Chief Medical Officer
Brill Pharma | Ramon J. Pons - Business Development Director
Pixium Vision | Lloyd Diamond - CEO
Re-Vana Therapeutics | Michael O'Rourke - CEO
Recornea | Emiliano Lepore - CEO
Radiance Therapeutics | Laurence Marsteller, MSc, MD - CEO
Aerie Pharmaceuticals | David A. Hollander, MD, MBA - Chief Research & Development Officer
Lumithera | Clark E. Tedford, PhD - President & CEO
Samsara Vision | Tom Ruggia - President & CEO
2:05 - 3:00 PM
What it Takes to be Successful in the European Market
Panelists:
Fabrizio Chines, Chairman, President & CEO - SiFi
Tim Clover, CEO - Rayner
Luis Iglesias, Corporate Officer & President and Head, EMEA - Santen
Karen Netherton, Global Patient Access Head, Ophthalmology - Novartis
Syed Rashid, Director of Market Access & Sales Training Europe, Middle East & Africa (EMEA), Surgical - Johnson & Johnson Vision
Moderated By:
Mark Mayhew, Partner - Emmetropes
3:00 - 4:00 PM
Virtual Networking
PROUDLY SPONSORED BY:
Gold Sponsor
Bausch + Lomb
Bausch + Lomb, a wholly owned subsidiary of Bausch Health Companies, is one of the world's best-known and most respected health care brands, solely focused on protecting, enhancing and restoring people's eyesight.
Silver Sponsors
Aerie Pharmaceuticals
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for open-angle glaucoma, ocular surface diseases and retinal diseases. In the U.S., Aerie markets Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor, and Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Aerie is expanding globally, with offices in Europe and Japan, and a manufacturing facility in Ireland. Rhokiinsa® (netarsudil ophthalmic solution) 0.02% and Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% are approved in the EU. A Phase 3 study of netarsudil ophthalmic solution is underway in Japan, in collaboration with Santen. Aerie is also pursuing additional candidates in ophthalmology, including a Phase 2b dry eye program with AR-15512 (TRPM8 agonist), and two clinical-stage retina programs, AR-1105 (dexamethasone) Sustained Release Implant and AR-13503 (Rho kinase/Protein kinase C inhibitor) Sustained Release Implant. Aerie continues to investigate assets from its proprietary library of small-molecule multi-kinase inhibitors.
Alcon
Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people worldwide see better. Through Surgical, Pharmaceutical and Vision Care, Alcon offers the world’s widest spectrum of ophthalmic products, helping millions of patients see the world better with clarity, color and beauty.
Novartis
Novartis is a leading ophthalmology company, with therapies that treat both front and back of the eye disorders, including retina diseases, glaucoma, dry eye and other external eye diseases. In 2016, approximately 200 million patients worldwide were treated with Novartis ophthalmic products.
Promedica International
Promedica International is a privately held, full-service, ISO-certified CRO providing clinical trial services for the medical device, biotechnology and pharmaceutical industries. Founded in 1985, Promedica International, a woman-owned corporation, is headquartered in Orange County, California. We have successfully been providing exceptional value to our clients for over 30 years in clinical trial project management, site recruitment and management, clinical study monitoring, data management, biostatistics, medical writing and GCP auditing.
Bronze Sponsors
GenSight Biologics
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), has been submitted for marketing approval in Europe for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
Johnson & Johnson Vision
At Johnson & Johnson Vision, we have a bold ambition: to change the trajectory of eye health. Through our operating companies, we've developed solutions for every stage of life-to help people see better, connect better and live better. We partner with eye care professionals to provide some of the world's leading products and technologies to address refractive error, cataracts, dry eye, and beyond. We are committed to using our reach and size for good and strive to put quality eye care within reach of everyone, everywhere.
LumiThera
LumiThera is committed to creating brighter horizons for patients by developing treatment solutions utilizing Photobiomodulation to improve visual function, to stop or slow the progression of debilitating eye diseases, and to prevent vision loss and blindness.
LumiThera’s first product, Valeda Light Delivery System®, is the first approved treatment for Dry Age-Related Macular Degeneration using Photobiomodulation. Valeda improves visual acuity, improves contrast sensitivity, reduces central drusen volume, and is designed for ease-of-use in the clinician’s office.
Valeda is CE Marked in Europe and is in clinical trials and not approved for use in the United States. Visit www.lumithera.com to learn more.
Radiance Therapeutics
Radiance Therapeutics is a British-American company, commercializing an important therapeutic advance in the treatment of glaucoma originating at Moorfields Eye Hospital and University College London, the world’s leading partnership for innovation in ophthalmology.
Glaucoma is the leading cause of irreversible blindness worldwide. Recognized by the ophthalmic community as a critical unmet need, current standard of care glaucoma drainage surgery (trabeculectomy and trans-scleral MIGS) fails in 50% of patients by three years, due to postoperative scarring. This leads to elevated IOP, and progressive vision loss. This is an outsized failure rate with a devastating impact: blindness.
RadianceTx is commercializing a proprietary medical device to address this high failure rate. Utilizing beta therapy, clinically proven in randomized controlled trials to significantly improve outcomes, this disruptive technology has the potential to revolutionize the treatment of glaucoma and save patients from blindness.
MEDIA PARTNERS:
